Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA.
Lancet Haematol. 2022 Feb;9(2):e143-e161. doi: 10.1016/S2352-3026(21)00283-0.
Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.
由于疾病、治疗和宿主相关因素的累积效应,感染仍然是多发性骨髓瘤患者发病和死亡的主要原因。鉴于感染风险随着疾病的发展而累积,预防感染至关重要。最佳的预防策略包括针对常见病原体的疫苗接种、抗菌药物预防、感染控制措施以及一小部分患者的免疫球蛋白替代治疗;然而,目前尚无普遍接受的感染预防指南。本综述提供了一份共识声明,该声明由来自全球的 36 名专家组成的小组提出,该小组由国际骨髓瘤学会召集,旨在回顾现有文献和当前指南,讨论与新兴疗法背景下多发性骨髓瘤感染风险和预防感染并发症相关的问题,并为预防这些并发症提供建议。